AI-generated analysis. Always verify with the original filing.
Halozyme Therapeutics, Inc. filed an 8-K on March 12, 2026, with Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements, as indicated by the external item hint. Exhibit 99.1 is a press release dated March 12, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On Marc
Financial Statements and Exhibits. Exhibits Exhibit No. Description 99.1 Press Release of Halozyme Therapeutics, Inc. dated March 12, 2026 104 Cover Page Intera